| DC74735 |
BCAT-IN-4 |
BCAT-IN-4 (Compound 1) is a BCAT inhibitor. |
|
| DC74736 |
HA5 |
HA5 inhibits Streptococcus mutans biofilm. |
|
| DC74737 |
Antitumor agent-109 |
Antitumor agent-109 (compound 6) is an inhibitor of hyaluronic acid (HY-B0633A) targeting to CD44. |
|
| DC74738 |
HDAC-IN-58 |
HDAC-IN-58 is a HDAC inhibitor. |
|
| DC74739 |
rac-Vestitone |
Vestitone reductase catalyzes a stereospecific NADPH-dependent reduction of (3R)-vestitone in the bio sysnthesis of antimicrobial isoflavonoid phytoalexin medicarpin. |
|
| DC74740 |
URAT1 inhibitor 7 |
URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor. |
|
| DC74741 |
FC-116 |
FC-116 is a Tubulin inhibitor that effectively inhibits tumor growth in mice. |
|
| DC74742 |
STAT3-IN-15 |
STAT3-IN-15 is a potent and orally active STAT3 inhibitor. |
|
| DC74743 |
sEH inhibitor-14 |
sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. |
|
| DC74744 |
BBT |
BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). |
|
| DC74745 |
(-)-GSK598809 free base |
(-)-GSK598809, also known as (1S,5R)-GSK598809, is a selective D(3)R antagonist recently progressed in Phase I trials. GSK-598809 may decrease the rewarding effects of contextual cues associated with drug intake preclinically, which may reduce drug craving in humans. |
|
| DC74746 |
DC-Y13-27 |
DC-Y13-27, a derivative of DC-Y13, is a YTHDF2 inhibitor (KD: 37.9 μM). |
|
| DC74747 |
Xanthine oxidoreductase-IN-4 |
Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor. |
|
| DC74748 |
O4I4 |
O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability. |
|
| DC74749 |
Mtb-IN-2 |
Mtb-IN-2 (compound 10c) is an antimicrobial agent against Mycobacterium tuberculosis (Mtb). |
|
| DC74750 |
Kanamycin A sulfate |
Kanamycin, also known as kanamycin A, is an aminoglycoside bacteriocidal antibiotic, available in by mouth, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. Kanamycin interacts with the 30S subunit of prokaryotic ribosomes. It gives birth to substantial amounts of mistranslation and indirectly inhibits translocation during protein synthesis. |
|
| DC74751 |
SAR407899 free base |
SAR407899 is a potent and selective Rho kinase inhibitor with promising antihypertensive activity. SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. SAR407899 is equipotent against human and rat-derived Rho-kinase 2 with inhibition constant values of 36 nM and 41 nM, respectively. SAR407899 is approximately 8-fold more active than fasudil. SAR407899 potently (mean IC(50) values: 122 to 280 nM) and species-independently relaxed precontracted isolated arteries of different species and different vascular beds. The antihypertensive effect of SAR407899 was superior to that of fasudil and Y-27632. |
|
| DC74752 |
SARS-CoV-2-IN-39 |
SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. |
|
| DC74753 |
L-Tyrosinol HCl |
L-Tyrosine is an aromatic, polar, non-essential amino acid that contains a highly reactive α-amino, α-carboxyl, and phenolic hydroxyl group. L-tyrosine modulates biofilm formation of Bacillus cereus ATCC 14579. L-Tyrosine Limits Mycobacterial Survival in Tuberculous Granuloma. |
|
| DC74754 |
SB-277011 HCl |
SB-277011, also known as SB-277011-A, is an orally active, potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. SB-277011 potentiated phMRI response to acute amphetamine challenge in the rat brain. SB-277011 attenuated ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. |
|
| DC74755 |
Prulifloxacin |
Prulifloxacin, also known as NM-441, is an inhibitor of bacterial DNA gyrase used to treat urinary tract infections. Prulifloxacin is an oral fluoroquinolone with a broad in vitro activity spectrum against Gram positive and negative bacteria and among fluoroquinolones has the lowest power of inducing resistance. In vitro and in vivo studies have shown its clinical efficacy and pathogen eradication. |
|
| DC74756 |
(-)-GSK598809 HCl |
(-)-GSK598809 is an isomer of GSK598809. GSK598809 is a selective D(3)R antagonist recently progressed in Phase I trials. GSK-598809 may decrease the rewarding effects of contextual cues associated with drug intake preclinically, which may reduce drug craving in humans. |
|
| DC74757 |
Tirabrutinib free base |
Tirabrutinib, also known as ONO-4059 and GS-4059, is a potent and orally active Bruton agammaglobulinemia tyrosine kinase (BTK) in hibitor. Upon administration, ONO-4059 covalently binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development. As a result, this agent may inhibit the proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. |
|
| DC74758 |
Rupatadine Fumarate |
Rupatadine Fumarate, also known as Rupatadine, is a second-generation H1-antihistamine with dual affinity for histamine H1 and PAF receptors. Rupatadine is indicated for the treatment of allergic rhinitis and urticaria. |
|
| DC74759 |
GSK-1034702 |
GSK-1034702 is a potent M1 receptor allosteric agonist. GSK-1034702, a selective M(1) receptor allosteric agonist, may have therapeutic benefits in disorders of impaired learning including Alzheimer's disease. |
|
| DC74760 |
Sonidegib phosphate |
Sonidegib (also known as erismodegib, LDE225, and NVP-LDE225) is an orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Erismodegib selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. It was approved by the FDA for treating basal cell carcinoma in July 2015. |
|
| DC74761 |
MPEP HCl |
MPEP is a selective mGluR5 antagonist. MPEP reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice. MPEP elevates accumbal dopamine and glycine levels; interaction with strychnine-sensitive glycine receptors. MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: significance for the use as anxiolytic/antidepressant drug. |
|
| DC74762 |
S1R agonist 2 |
S1R agonist 2 (Compound 8b) is a selective S1R agonist. |
|
| DC74763 |
CpCDPK1/TgCDPK1-IN-3 |
CpCDPK1/TgCDPK1-IN-3 (Compound 20) is a CpCDPK1 and TgCDPK1 inhibitor |
|
| DC74764 |
DOTMA E-isomer |
DOTMA E-isomer is a trans-isomer of DOTMA, in which two double bonds are trans-configuration (configuration of a geometrical isomer in which two groups are on opposite sides of an imaginary reference line on the molecule). DOTMA E-isomer is a useful cationic lipid for gene transfection, nucleic acids delivery, plasmid stabilization. Note: DOTMA is the Z-isomer (or Cis-isomer) chloride salt, which CAS# is 104162-48-3. While DOTMA E-isomer (trans-isomer) chloride salt has CAS#104872-42-6. Some vendors confused each other. |
|
